首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2136463

2020-2026年中樞神經系統領域的合作與授權協議

Central Nervous System Collaboration and Licensing Deals 2020-2026

出版日期: 2026年10月01日 | 出版商:

Current Partnering | 英文 500+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2020-2026年中樞神經系統領域的合作與授權協議

讓我們透過分析基於 966 個案例研究的合作與授權協議數據，來了解中樞神經系統 (CNS) 領域合作的趨勢。

《2020-2026 年中樞神經系統 (CNS) 合作與許可協議》提供了有關 966 項與 CNS 相關資產、技術和開發計劃的合作協議的全面資訊。

中樞神經系統領域的合作涵蓋了不同的治療適應症、技術和開發階段，每筆交易的交易結構都反映了每個機會的科學複雜性、開發風險和商業性潛力。

本報告將這些趨勢匯總到一個資源中，使用戶能夠了解誰在合作、哪些與中樞神經系統相關的機會吸引了人們的興趣、交易的結構、披露的財務條款以及交易如何根據治療適應症、技術和開發階段而有所不同。

這份報告不只是簡單地列出了交易清單；它結合了全面的市場交易分析和財務基準、主要交易商的信息、詳細的交易記錄以及公開的合約文件。

本報告為參與中樞神經系統 (CNS) 合作的業務發展、許可、交易來源和評估、公司策略、研發策略、競爭情報分析以及法律團隊提供了實用的資訊來源和基準資源。

了解中樞神經系統 (CNS) 領域的合作趨勢

本報告分析了2020年至2026年中樞神經系統（CNS）產業的交易情況，內容包括：

CNS 合作夥伴關係年度趨勢
按交易類型分類的交易趨勢
產業部門
合作關係發展階段
技術類型
中樞神經適應症
中樞神經系統（CNS）領域最活躍的交易商。
根據已披露的交易金額，主要交易
中樞神經系統（CNS）內協作活動的趨勢
這使用戶能夠確定其活動重點領域，並了解哪些公司、技術、開發階段和治療領域引起了合作興趣。
中樞神經系統 (CNS) 交易的財務狀況基準
財務條款可能因 CNS 資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析，包括以下內容：

交易總額
預付款
里程碑付款
版稅率
透過分析這些基準背後的具體交易，用戶可以更全面地了解所揭露的經濟數據背後的經濟狀況。
這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
財務基準只有在結合類似交易的結構和情況進行解讀時，才能發揮其最大效用，而不僅僅將其視為平均值。本報告提供了建構這種背景所需的交易基本資訊。
確定中樞神經系統領域的關鍵交易商和潛在的未來合作夥伴。
本報告列出了在 CNS 領域合作活動最活躍的公司，並提供了詳細的交易歷史記錄，以便用戶可以調查這些公司過去的活動。

這有助於用戶識別以下內容：

積極尋求中樞神經系統（CNS）機會的公司
有前景的許可和合作夥伴
我們曾多次與一些機構就特定中樞神經系統適應症合作。
積極參與開發過程的公司
交易商對特定技術或模式表現出興趣
競爭對手採取類似的外部創新策略
對於尋求中樞神經系統 (CNS) 資產和技術合作夥伴的公司而言，過去的交易歷史可以提供寶貴的見解，了解哪些組織對類似的機會表現出了興趣。
本研究比較了各種中樞神經系統 (CNS) 疾病的協作活動。
中樞神經系統涵蓋廣泛的治療適應症，包括神經系統疾病、神經退化性疾病及相關疾病，每種疾病都有其獨特的發展和合作趨勢。
本報告按中樞神經系統治療適應症分析交易，使用戶能夠專注於與特定項目或策略領域最相關的交易，而不是依賴廣泛的市場層級基準。
透過結合基於技術和發展階段的分析，使用者可以識別出更有意義的類似交易和潛在的未來合作夥伴。
了解中樞神經系統合約的結構
本報告涵蓋聯合開發、授權、研發及其他合作交易。

根據交易詳情和資訊披露，用戶可以調查以下方面：

授予和保留的權利
研究與開發職責範圍
授權權
獨家版權
區域權利
智慧財產
發展和監管義務
生產和供應責任
商業化權利
金錢補償
里程碑和版稅
管治
合約期限和終止條款
在考慮 CNS夥伴關係關係的合適結構時，這些例子可以作為有用的參考。
從實際合約文件中學習
本報告提供部分 CNS 交易的原始合約文件的查閱權限（如有）。

這些合約提供的資訊遠比簡單的標題公告所能展現的要詳細得多，使用戶能夠檢驗公司如何記錄諸如以下事項：

權利範圍
發展義務
智慧財產
獨家版權
財務狀況
里程碑達成條件
特許權使用費規定
商業化權利
合約終止及其他談判事項
對於準備和與 CNS 協商合作及許可協議的團隊來說，能夠獲取實際的合約措辭，可以深入了解類似交易的實際結構。
CNS交易綜合目錄
本報告包含一個涵蓋 966 項 CNS 合作及授權協議的綜合目錄，提供了識別相關領先交易的詳細資訊來源。

交易記錄可依以下類別查看：

公司
技術類型
治療適應症
合約揭露狀態
每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
誰該使用這份報告？
業務拓展與授權團隊
識別類似的 CNS 交易、潛在合作夥伴和相關交易結構。
探勘與評估團隊
我們尋找那些在特定適應症、技術和發展階段積極探索中樞神經系統業務機會的公司。
尋求合作夥伴的生技公司
找出對類似的中樞神經系統 (CNS) 資產、技術和開發計劃表現出明確興趣的組織。
企業策略與研發策略團隊
我們將了解我們的競爭對手和潛在合作夥伴如何透過外部創新來建立他們的中樞神經系統產品線。
競爭情報與市場情報團隊
我們按公司、適應症、開發階段和技術追蹤合作趨勢，以了解不斷變化的策略重點。
法律及交易團隊
我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
我們將市場範圍內的 CNS 情報轉化為公司特定的見解。
符合資格的客戶將收到 Current Partnering 的報告，以及為高階主管量身訂製的合作關係簡報。
本次簡報將根據 CNS 交易資訊分析您的資產、技術、指標或合作目標。
如有需要，我們可以提供相關的類似交易、有前景的合作夥伴、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您特定情況選擇的資訊。
請索取樣本或聯絡 Current Partnering 討論報告內容以及我們是否可以為貴公司提供客製化分析。

基於中樞神經系統治療標靶的交易
交易目錄
交易目錄 - 按公司名稱分類的中樞神經系統交易（AZ）
交易目錄 - 按技術類型分類的中樞神經系統交易
交易類型的定義
關於生物製藥研究
Current Partnering
Current Agreements
理想合作夥伴近期報告標題

簡介目錄

Product Code: CP2203

Central Nervous System (CNS) Collaboration and Licensing Deals 2020-2026

Understand the CNS partnering landscape using intelligence from 966 real-world collaboration and licensing deals.

Central Nervous System (CNS) Collaboration and Licensing Deals 2020-2026 provides comprehensive intelligence on 966 partnering deals involving CNS assets, technologies and development programs.

CNS partnering spans a diverse range of therapeutic indications, technologies and stages of development, with deal structures reflecting the scientific complexity, development risk and commercial potential of individual opportunities.

The report brings this activity together in one resource, enabling users to understand who is partnering, which CNS opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in CNS partnering.

Understand the CNS partnering landscape

The report analyzes CNS dealmaking from 2020 to 2026, including:

Trends in CNS partnering by year
Deal activity by deal type
Industry sector
Stage of development at the time of partnering
Technology type
CNS therapeutic indication
Most active CNS dealmakers
Leading deals by disclosed value
How CNS partnering activity is evolving
This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
Benchmark CNS deal financials
Financial terms can vary considerably according to the CNS asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

Headline deal values
Upfront payments
Milestone payments
Royalty rates
Users can then investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading CNS dealmakers and prospective partners
The report identifies the most active companies in CNS partnering and provides extensive transaction histories that enable users to investigate their previous activity.

This can help users identify:

Companies actively seeking CNS opportunities
Prospective licensing and collaboration partners
Organizations repeatedly partnering in particular CNS indications
Companies active at relevant stages of development
Dealmakers demonstrating interest in specific technologies or modalities
Competitors pursuing similar external innovation strategies
For companies seeking to partner a CNS asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
Compare partnering activity across CNS indications
CNS encompasses a broad range of distinct neurological, neurodegenerative and related therapeutic indications, each with its own development and partnering dynamics.
The report analyzes deals by CNS therapeutic indication, allowing users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic area.
Combined with analysis by technology and development stage, this enables users to identify more meaningful comparable deals and prospective partners.
Understand how CNS agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

Rights granted and retained
Research and development responsibilities
Licensing rights
Exclusivity
Geographic rights
Intellectual property
Development and regulatory obligations
Manufacturing and supply responsibilities
Commercialization rights
Financial consideration
Milestones and royalties
Governance
Term and termination provisions
These real-world examples provide useful reference points when considering the appropriate structure for a CNS partnership.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected CNS transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

Scope of rights
Development obligations
Intellectual property
Exclusivity
Financial terms
Milestone triggers
Royalty provisions
Commercialization rights
Termination and other negotiated provisions
For teams preparing or negotiating a CNS collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
Comprehensive CNS deal directory
The report includes a comprehensive directory of 966 CNS collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

Company
Technology type
Therapeutic indication
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable CNS transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking CNS opportunities across particular indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable CNS assets, technologies and development programs.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building CNS pipelines through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide CNS intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying CNS deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.